Abstract 950P
Background
In this study, we aimed to evaluate the safety and efficacy of combining PD-1 antibody Tislelizumab with Sorafenib for the treatment of advanced hepatocellular carcinoma(HCC). Additionally, we sought to investigate the relationship between the circulating tumor cells (CTCs) count/ programmed death-ligand 1 (PD-L1) expression of CTCs and the prognosis of patients with advanced hepatocellular carcinoma.
Methods
The study Enrolled patients (pts) with unresectable HCC patients (pts) to receive tislelizumab combined with sorafenib. Tislelizumab, 200mg/q3w intravenous infusion, sorafenib 400 mg/bid oral dose; Evaluate every 3 cycles (9 weeks) to evaluate the safety and effectiveness of the drug regimen CTCs count and PD-L1 expression of CTCs were performed in all patients before enrollment. Primary endpoint was ORR by RECISTv1.1 per investigators. The secondary endpoints aimed to assess the relationship between the count of CTCs or the expression of PD-L1 and the prognosis of HCC.
Results
As of November 2022, 32 patients were enrolled in the study received combination treatment. For 32 pts, ORR was 17% (95% CI 33.0%-75.2%) and DCR was 65% (95% CI 71.2%-91.9%) by RECIST v1.1. When evaluated by mRECIST, ORR and DCR improved to 24.2% (95% CI 55.8%-93.8%) and 75% (95% CI 74.2%-92.9%), respectively. Treatment-emergent adverse events (TEAEs) occurred in 75% of pts, 35% of which was ≥grade 3. Of which 31 patients (96.8%) were positive for CTC, ranging from 1 to 45, with a median of 7 (3, 11), 25 (78.1%) PD-L1+CTC was detected in 32 patients. The median follow-up time was 6 months (range, 2-14 months). Correlation analysis found that The 1-year progression-free survival rates of patients in the PD-L1+CTC group and those in the non-detected PD-L1+CTC group were 54.1% vs 28.6% respectively (P=0.036).
Conclusions
Tislelizumab combination with Sorafenib showed promising antitumor activity with relatively high ORR and a tolerable safety profile in 1st line HCC treatment. Baseline CTC PD-L1+ can be used as a predictive indicator for screening HCC patients for PD-1/PD-L1 blockade therapy, and dynamic measurement of CTC changes can monitor the therapeutic effect of patients.
Clinical trial identification
ChiCTR2100050076.
Editorial acknowledgement
Legal entity responsible for the study
Che Xu.
Funding
Sanming Project of Medicine in Shenzhen (No.SZSM202011010) and Shenzhen High-level Hospital Construction Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18